Technology Holding, LLC — Department of Defense STTR Phase I: AF15-AT29

Description

ABSTRACT: Elimination of the cold chain is of vital importance for the ability to treat injured warfighters in the field and behind enemy lines. The application of an already FDA approved reagent for the stabilization of labile reagents will allow for minimal development time delaying the fielding of a new technology to fill this role. Collagen has been used extensively since the 1980s as an approved injectable by the FDA. Further, collagen is classified as being generally recognized as safe (GRAS) allowing for the development of both oral and injectable formulations. This reagent belongs to the protein polymer class which has already shown promise in the proposed application. Further development of collagen to fill this role is warranted.; BENEFIT: Elimination of the cold chain through reagent stabilization with collagen will have benefits not only for DoD application but also in the civilian market. By removing the necessity for refrigeration vaccines and temperature sensitive drugs can be transported and stored more easily. This will reduce the cost of medical care and increase the penetration of vaccines and medicines beyond stable power grids currently necessary to ensure activity of the vaccines and drugs. This has the potential to not only aid the third world, but prevent vaccine spoilage which occurs frequently in the first world leading to destruction of up to half of the world supply of vaccines. This waste leads to increased costs and shortages which can be prevented.